Background {#Sec1}
==========

Tobacco dependence is recognized as a mental and behavioral disorder in the International Classification of Diseases (ICD-10) of the World Health Organization (WHO) \[[@CR1]\] and in the Diagnostic and Statistical Manual of Mental Disorders of the American Association of Psychiatry (DSM-V-TR) \[[@CR2]\]. Patients with serious mental disorders have a greater prevalence of tobacco use \[[@CR3]\], more severe psychiatric symptoms, poorer overall general well-being, and greater functional impairment when compared to non-tobacco users \[[@CR4]\].

'The likelihood that a person who smokes has a mental disorder is twice that of a person who does not have one'. \[[@CR5], [@CR6]\] The proportional relationship between the intensity of the psychiatric symptoms and the severity of the tobacco dependence has already been established \[[@CR6], [@CR7]\]. Tobacco-related illnesses including cancer, heart disease, and lung disease are among the most common causes of death among persons with mental illness. Globally individuals with serious mental illness and substance abuse on treatment in the public health system die, on average, 25 years earlier than those without mental illness \[[@CR8]\].

According to World Health Organization (WHO), Quality of Life (QOL) definition is individualistic, has a cultural and value systems dimension in relation to the persons goals, expectations, standards and concerns. WHO recognizes 5 domains that should be captured while assessing quality of life: Physical, Psychological, social, environmental, and spiritual \[[@CR9]\]. With the rate at which a person with mental illness smokes, they are more likely to suffer from the physical domain, due to the health impact of tobacco use. QOL has been said to involve two dimensions -- adaptive functioning (self-care and social roles) and life satisfaction or subjective wellbeing \[[@CR10]\]. Most people with mental illness need support to balance their emotional and physical needs.

Randomized controlled trials have shown that tobacco cessation treatment among patients receiving concomitant mental health treatment is effective and safe, does not exacerbate mental health symptoms, and does not lead to increased use of alcohol or illicit drugs \[[@CR11]--[@CR13]\]. However, most research on the efficacy and safety of tobacco cessation interventions has excluded participants with a past or present history of mental illness; thus, this population has remained underrepresented in randomized trials of tobacco cessation intervention strategies \[[@CR14]\].

Morris et al. \[[@CR15]\] found that most mental health providers receive little or no training on smoking cessation and frequently have misconceptions, such as that patients with mental illnesses need to use tobacco to control their psychiatric symptoms and that these individuals have no desire to quit. A 2013 Cochrane systematic review \[[@CR16]\] demonstrated how myths have led to persistently high tobacco use among the mentally ill, including myths that persons suffering psychological disorders lack motivation for tobacco cessation, that individuals with mental illness do not have the capacity to quit and that efforts to quit may actually impede their mental health treatment. Because of this misinformation, lack of awareness and smoking cessation interventions competence, tobacco use among this special group has been overlooked, depriving mental health patients of the necessary interventions for its control and prevention \[[@CR17]\].

Few studies have focused on group behavioral interventions without addition of pharmacotherapies among this group, and few, if any, of these studies have been performed in Africa. In Kenya, there is limited access to tobacco cessation pharmacotherapies, which are also not affordable to most of this population. Because of the need, this study sought to evaluate the efficacy and safety of a group tobacco cessation behavioral intervention among patients with mental illness who attend outpatient programs at Mathari Referral and Teaching Hospital in Nairobi.

Objectives {#Sec2}
----------

To determine the efficacy and safety of a group tobacco cessation behavioral intervention among tobacco using patients with mental illnesses on tobacco cessation at 6 months.To evaluate the impact of tobacco cessation on health-related quality of life of patients with mental illnesses.

Methods/ design {#Sec3}
===============

Study design {#Sec4}
------------

This study used a controlled clinical trial design.

Study setting {#Sec5}
-------------

This study was conducted at Mathari Referral and Teaching Hospital Clinic for Substance Abuse Treatment (CSAT) and outpatient follow-up clinics. Mathari Referral and Teaching Hospital is Kenya's only national referral and teaching psychiatric hospital with a capacity of 700 beds. The staff who provide services at the hospital include 243 nurses, 7 psychiatrists (2 of whom are full-time administrators), 2 pharmacists, and support staff. Tobacco cessation therapy was provided by trained tobacco cessation counsellors. The study was conducted at the CSAT and other outpatient clinics.

Sample size calculation \[[@CR18]\] {#Sec6}
-----------------------------------

The sample size necessary for comparing proportions includes: proportion *p*~*1*~ being the estimated proportion of study participants with improved health status after the intervention and *p*~*2*~ being the estimated proportion of study participants with improved health outcomes in the control group.
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Inclusion criteria {#Sec7}
------------------

18 years of age and above.History of tobacco use for more than 6 months.A Fagerstrom score of 6 and above, which is a threshold consistent with dependence \[[@CR17]\].Currently on outpatient follow up treatment for a diagnosed mental health condition.Willing to be part of the study for 6 months.

Exclusion criteria {#Sec8}
------------------

Patients on nicotine replacement therapy (NRT) or other pharmacotherapy for tobacco cessation.Patients currently experiencing severe psychotic episodes judged by their treating health care provider.Patients who would not be able to commit to the group sessions, defined as those who would not be able to attend group sessions for any reason, including transport-related reasons.

Recruitment {#Sec9}
-----------

Prior to recruitment, YO trained 2 counsellors or nurses who assisted with recruitment, screening, intake, and registration. Three addiction therapists who did not work at the hospital were trained by YO to lead tobacco cessation groups tailored to psychiatric patients. All patients who were enrolled for follow-up programs at CSAT and follow-up clinics were asked about their history of tobacco use by the intake/registration nurses.

All patients who walked in for follow-up after hospital discharge for a primary mental health diagnosis were informed of the study and were invited to participate. Informed consent was obtained from individuals who had capacity to provide informed consent in the presence of the clinicians working with the participants to ensure they understood the study requirements. Individuals who did not have capacity to provide informed consent were not recruited to minimize potential risks to this vulnerable population. After providing informed consent, participants were asked to complete the Fagerstrom tobacco use test. Participants were then asked to complete sociodemographic questionnaire and the World Health Organization (WHO) quality of life questionnaire. This screening and recruitment continued until the number of participants who provided informed consent reached 100.

Randomization/allocation {#Sec10}
------------------------

Participants were recruited in clusters of 10 for allocation into the intervention and control groups. The first 10 participants formed group 1, and the next 10 participants formed group 2. Group 1 became the first intervention group, while group 2 became the first control group. This procedure continued until all 10 groups were formed (5 intervention and 5 control groups).

Participants were followed up clinically for ongoing mental health care on their regular clinic days.

Study intervention {#Sec11}
------------------

5As-based brief advice was offered to the intervention group participants by the study team who were trained by YO. This brief advice consisted of an individual session lasting approximately 5 min for each participant immediately after their consent had been obtained. The focus of the 5As was to enable the therapist know the immediate concern of each participant and to enable adequate support when the particular issues were raised during the group intervention sessions. The behavioral group intervention consisted of 6 sessions over 12 weeks and were led by 2 trained facilitators, followed by monthly group meetings from weeks 14 to 26. This program was adapted from the Royal Australian College of General Practitioners' *Supporting Smoking Cessation Guide for Health Professionals* \[[@CR19]\] and the World Health Organization's *Strengthening Health Systems for Treating Tobacco Dependence in Primary Care* training package \[[@CR20]\].

The topics that were explored during the group sessions include: Introduction to the Program and Reasons to QuitBenefits of Quitting and Understanding Why We Smoke and Ways of QuittingWithdrawal Symptoms and Social SupportDealing with Stress and Anxiety and Coping with Depression due to withdrawalAssertiveness Training and Anger ManagementTobacco-Free Lifestyle and Dealing with High Risk Situations

### Group session 1 (week 1) {#Sec12}

On the first session, participants were introduced to the study program and specific components of the group behavioral intervention. Participants shared their expectations and experiences in their goal of tobacco cessation. The estimated time for group session 1 was 30--45 min.

### Group sessions 2--6 (weeks 2--11) {#Sec13}

Participants set their anticipated quit date on the 2nd week, which was their second session. During weeks 2 through 11, before the start of the session, feelings of participants were explored, the previous week's self-reported tobacco consumption or cessation attempt was recorded. The topic of each week was explored first by lecture to explain the topic, and then group members took turns sharing their experiences on the topic.

### Group sessions 7--9 (weeks 14--26) {#Sec14}

Participants continued attending the CSAT outpatient and ward follow-up programs during this period. Behavioral group sessions 7--9 (weeks 14--26) were conducted once a month by the facilitators whereby each session was begun with a round of discussion on how participants were feeling about their cessation attempts, including any challenges they had experienced. The self-reported amount of tobacco used and quit attempts were documented. The study team also documented the challenges raised and tried to offer practical and supportive therapy for the challenges.

Summary of the group sessions and topics can be found in Table [1](#Tab1){ref-type="table"}. Table 1Group sessions and topics summaryTime FrameGroup sessionsAfter signed consent5 AsAsk- History of tobacco useAdvice- On need to quit tobacco use, and inform on effects of tobacco useAssess- On readiness to quit tobacco use, if not ready use motivational skills to increase readinessAssist- Offer intervention support. Inform on behavioral coping skills and available pharmacotherapiesArrange- Arrange date, time and place of next session to introduce coping skills)Session 1 (Week 1)7. Introduction to the program and reasons to quit tobacco useSession 2 (Week 3)8. Benefits of quitting and understanding why we smoke and ways of quitting9. setting quit dateSession 3 (Week 5)10. Withdrawal symptoms and social supportSession 4 (Week 7)11. Dealing with stress and anxiety and coping with depressionSession 5 (Week 9)12. Assertiveness training and anger managementSession 6 (Week 11)13. Tobacco-free lifestyle and dealing with high risk situationsFollow up sessions (Weeks 14--26)14. Round of discussion on participants' feelings, cessation attempts, challenges experienced, and how they coped15. Documentation of self-reported quit attempts16. Supportive therapy

Baseline and follow-up assessments {#Sec15}
----------------------------------

During baseline, Age of first use, duration of use, amount used, mental illness managed, Fagerstrom test score, and other substances used were documented. During weeks 4, 12 and 26, Quit attempts made, amount currently being smoked and Cotinine test results were documented. During week 26, the WHOQOL questionnaire was re-administered.

Based on previous tobacco cessation intervention trials, it was assumed that those who did not report abstinence had positive cotinine results.

At the group assessments (Weeks 4, 12, and 26), participants who reported continued tobacco use abstinence and consented to a saliva test were tested using a nicotine cotinine strip (Devon Medical: Nicotine/tobacco test kit). The saliva tests were evaluated by the nurses working at the hospital who were blinded to treatment allocation and were not otherwise part of the study.

The summary of the follow-up assessment activities is reported in Table [2](#Tab2){ref-type="table"}. Table 2Baseline, Follow-up activities and Data to be collected summaryFollow-up timeActivityDocumentationWeek 0(Baseline)• Socio-demographic questionnaire• Fagerstrom test for nicotine dependence• WHO quality of life (QOL) instrument• Age of first use, duration of use, amount used, mental illness managed, other substances used• Fagerstrom test score• WHO QOL scoreWeek 4• Explored progress made and documented quit attempts• Focused on challenges experienced and how they were managed• Documented number of sticks currently smoked• Those reporting complete cessation and who gave consent for saliva testing, were then screened using cotinine test• Quit attempts made• Amount currently being smoked• Cotinine testWeek 12• Explored progress made and documented quit attempts• Focused on challenges experienced and how they were managed• Documented number of sticks currently smoked• Those reporting complete cessation and who gave consent, were screened using cotinine test• Quit attempts made• Amount currently being smoked• Cotinine testWeek 26(Final follow-up)• Explored progress made and documented quit attempts• Focused on challenges experienced and how they were managed• Documented number of sticks currently smoked• Those reporting complete cessation, gave consent, then were screened using cotinine test• Administered WHO QOL instrument• Recorded quit attempts made• Amount currently being smoked• Cotinine test• WHO QOL score

Control group procedures {#Sec16}
------------------------

The control group was provided questionnaires to fill at the end of Weeks 4, 12, and 26. During the rest of the study, they continued receiving usual care, including clinical care at CSAT. After the conclusion of the study, the control group will be offered the group sessions that the intervention group received.

Outcome measures {#Sec17}
----------------

The study's primary outcome was self-reported continuous tobacco use abstinence, biochemically verified, at Week 26. It was estimated that the intervention would increase tobacco cessation from the current rate of 15 to 35% \[[@CR21]\]. While adjusting for 30% attrition rate, with a sample size of 48 per group, 96 participants would provide 80% power to detect this between-group difference with a two-sided alpha = 0.05.

Secondary outcomes assessed included cessation at Week 4 and 12, number of quit attempts, reduction in number of cigarettes used per day, and health-related quality of life measured at Week 26.

Research instruments {#Sec18}
--------------------

### 5As: stages in the process of smoking cessation {#Sec19}

The tobacco cessation research literature strongly supports the use of a comprehensive, clinic-based approach to tobacco cessation, known as the 5A's--- ask, advise, assess, assist, and arrange follow-up. Despite rates of performance of the ask, assess, and advise components of the 5A's model increasing and being effective, helping and arranging for follow-up components, are far less common \[[@CR22]\].

### Fagerstrom test {#Sec20}

The Fagerstrom Test for Nicotine Dependence (FTND) is a widely used and researched short questionnaire \[[@CR23]\]. The FTND has been found to have good test-retest reliability, convergent validity, and discriminant validity and performs well from a psychometric perspective with smokers with mental illness as it does with smokers without mental illness \[[@CR24]\]. Several studies analysis on the reliability index for the overall score on the FTND indicated that it was excellent (0.87). In 14 studies that evaluated the internal consistency of the FTND, the Cronbach's alpha coefficient ranged from 0.55 to 0.74, indicating that the FTND has moderate internal consistency \[[@CR25]\]. The FTND can be administered in an interview or tobacco users can self-administer the questionnaire. The score ranges from 0 to 10 points, and the mean score of representative samples of smokers is usually in the range of 3--4 points \[[@CR26]\].

### World Health Organization quality of Life-100 questionnaire {#Sec21}

The World Health Organization developed the World Health Organization Quality of Life-100 (WHOQOL-100) as a cross-cultural method of assessing QOL separate from a specific disease. Defining quality of life as an "individual's perceptions of their position in life in the context of the culture and value systems in which they live, and in relation to their goals, expectations, standards, and concerns" \[[@CR27]\], the WHOQOL-100 allows the respondent to determine his or her satisfaction while limiting constraints from cultural expectations or developer biases.

The WHOQOL-100 has been validated for use in a mental health population \[[@CR28]\].

Participants' incentives {#Sec22}
------------------------

Participants were reimbursed Kshs. 200 (approximately USD \$2) for transport and time spent at the hospital because of the study.

Project team {#Sec23}
------------

YO was the lead investigator and trained the research assistants, nurses, and counselors who were part of the study. 2 nurses who were part of the hospital staff, who were working at the outpatient registry were recruited to assist in identification of all patients who use tobacco and screened them for eligibility for the study.2 counselors who were not part of the hospital team were trained by YO in tobacco cessation group therapy to lead in facilitation of the group sessions and document the progress and findings.

Ethical considerations {#Sec24}
----------------------

The research proposal was presented to the department of Psychiatry University of Nairobi (UoN) for study clearance approval. The study and associated protocol were approved by the ethical committee of Kenyatta National Hospital in February 2017. The trial and its protocol were registered in May 2018 by the National Commission for Science, Technology and Innovation (NACOSTI); Permit No: NACOSTI/P/18/37962/21104.

Eligible participants for this study were those who were mentally stable and were in a position to provide informed consent. For those eligible participants who did not understand English nor Kiswahili, a translator was availed for them from a member of the research team trained in responsible conduct of research. If a translator was not readily available, then the participant was given another date to come back when a translator would be available. All participants were briefed on the purpose of the study. The study did not anticipate any more than minimal risk to the participants through their participation because those who had serious withdrawals, as described by the participants, would not be included and would be referred for appropriate interventions. YO is a trained mental health specialist, has been trained in research among vulnerable populations, oversaw the study interventions on site, and participated in facilitating the interventions.

Each screened individual was assured of confidentiality and allowed to ask questions or clarifications prior to participating in the study. Also, participants were enrolled using their client codes to protect their identities, and any identifying information was stored in a password-protected, securely stored file by YO. Considering that the study asked questions that might have made the respondents uncomfortable, those who chose to participate were informed of these risks during the informed consent process for the study, and they were also informed that they had the right to withdraw at any time without any repercussions. The study had safety precautions for participants such that any participant who was found to need further psychological services (e.g. severe withdrawal, confusion, or some form of psychosis) would be referred to the appropriate clinical program or facilities where necessary or advised to seek further management. No such measures were needed.

Dissemination of results is planned through publications in peer-reviewed journals and presentations in scientific conferences. Results will also be disseminated through presentations in local mental health meetings and within the study site. Data sharing maybe considered upon reasonable request.

Data management and analysis {#Sec25}
----------------------------

Data were collected using structured questionnaires and entered into a secure, password-protected database. The hard copy data forms have been stored in a lockable cabinet in lockable office during collection, data entry, analysis, and after study completion. Upon completion of data entry, 20% of hard copy forms will be compared with the entered data to identify systematic or random errors and corrections and repeated data entry will be made appropriately, including 100% recheck if a \> 2% error rate is detected.

Sociodemographic characteristics of the study participants, such as age, gender, residence, education level, occupation and perceived health status will be reported. We will also report participants' health-related quality of life at baseline using the WHOQOL-100 and document participants' primary mental health disorder. The kind of tobacco product under use, daily amount of tobacco consumption, duration of use, and age of initiation to tobacco will also be described. Using the Fagerstom test, we will determine nicotine dependency and describe intent to quit use of tobacco products. Data on any other substance use such as alcohol, bhang and miraa, including duration of use, will also be reported.

During exploratory data analysis, discrete variables will be summarized using frequencies and percentages, while continuous variables will be summarized using measures of central tendency and dispersion such as means with standard deviations and median with inter-quartile ranges, where appropriate. Bivariate analysis will be carried out to compare the intervention groups with the control groups with respect to socio-demographic characteristics, history of tobacco and substance abuse, type(s) of mental illness, and WHOQOL-100 scores at baseline. Mann Whitney tests will be employed to compare the intervention and control groups where predictor variables are continuous, and chi-squared tests will be applied when the predictor variable is categorical. We will compare unadjusted and adjusted cessation rates at 6 months, recognizing the limitations of the study design at eliminating potential confounders between the two groups given the non-randomized nature of group allocation. Potential confounders include age, sex, baseline tobacco, and baseline type of mental illness, among others. Time to cessation of tobacco use will be compared between the two groups by creating Kaplan-Meier curves and with the creation of corresponding Cox proportion hazard models to determine the effect of the intervention on the primary study outcome. We will report unadjusted and adjusted models, the latter which will aim to control for independent factors associated with relapse. We will perform similar analyses for secondary outcomes as well. All analyses will be carried out using IBM SPSS Statistics Software Version 24, and a two-sided *p* \< 0.05 will be used to determine statistical significance.

Discussion {#Sec26}
==========

This group tobacco cessation behavioral intervention among persons with mental illness seeks to identify a safe and effective intervention for this high-burden outpatient population in Kenya. The study methodology integrated the normal clinic attendance days and time to ensure convenience for the participants as well as no extra expense incurred. The goal is to demonstrate the feasibility of this accessible intervention to patients in need of accessible and affordable treatment options. This study intervention may guide cessation interventions among this group, as well as national and regional discussions among the low- and middle-income countries with limited access to tobacco cessation pharmacotherapies. It may also highlight the potential value of integrated cessation services, which might be safe, effective, cost-effective, and affordable, as well as the potential value of training of healthcare providers in tobacco cessation intervention among this population.

Strengths of the study {#Sec27}
----------------------

This is the first study focusing of its kind on this population that has been done in KenyaStudy was carried during normal clinic days, which encourages participationUse of group sessions that allowed participants to share their experiences (both good and bad) and normalize them.Followed up participants for 3 months after the intervention.The use of the hospital's clinicians during recruitment which made for familiar faces and made encouraged trust between the participants and the researchers.

Limitations of the study {#Sec28}
------------------------

The study did not explicitly ask about the participants desire to quit prior to recruitment.The study did not offer medication to participants with severe nicotine withdrawal; it referred them appropriately but they were discontinued from the study.Not all patients who wanted to quit tobacco use were recruited; only those who scored 6 on the Fagerstrom Nicotine test were recruited.Under 18 years with nicotine dependence and a desire to quit were not enrolled in the study

Current status {#Sec29}
--------------

The trial started recruiting participants on 10th April 2017, with follow-up completed on 28th June 2019. Trial results will be available in August 2019.

CSAT
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